A study published in BJU International (2016) analyzed 40,533 men diagnosed with Gleason score 8 or 9 prostate cancer to compare prostate cancer-specific mortality (PCSM) rates. The study found that patients with Gleason score 5 + 3 = 8 had a 5-year PCSM rate of 13.5%, which was similar to
This observational study investigated the prevalence of prostate cancer in 345 hypogonadal men with PSA levels of 4.0 ng/mL or less, finding a 15.1% overall cancer detection rate. The prevalence increased with PSA levels, ranging from 5.6% in men with PSA ≤1.0 ng/mL to 36.4% in those with PSA 3.1–4.0
This cross-sectional study examined prostate cancer patients’ understanding of the Gleason Scoring System (GSS) and its impact on shared decision-making. Despite 48% of participants holding a bachelor’s degree or higher, knowledge of the GSS was low (M = 1.8, SD = 1.4), while perceived importance of the GSS was moderate
This observational study evaluated the safety of testosterone replacement therapy (TRT) in 31 men with symptomatic hypogonadism after undergoing brachytherapy for early-stage prostate cancer. Over a median follow-up of 5 years post-brachytherapy, TRT increased median testosterone levels from 188 ng/dL to 498 ng/dL without causing biochemical recurrence. No patients experienced
This pilot study evaluated the safety and efficacy of BPC-157, a peptide not yet FDA-approved, in treating moderate to severe interstitial cystitis (IC) in patients unresponsive to standard pentosan polysulfate therapy. Twelve female participants aged 39 to 76 received a single 10 mg intravesical injection of BPC-157 around inflamed bladder
This observational study analyzed data from 6,549 men with erectile dysfunction (ED) to evaluate the relationship between erection hardness, assessed using the Erection Hardness Grading Scale (EHGS), and various measures of erectile function. Nearly 50% of men with severe ED (IIEF EF domain score ≤10) improved to no ED (IIEF
This case-control study examined the association between serum testosterone levels and prostate cancer risk, highlighting potential implications for testosterone therapy. Analyzing 794 male participants from the Baltimore Longitudinal Study of Aging, researchers found that men with higher free testosterone levels had a significantly increased risk of prostate cancer (RR 2.59,
This randomized controlled trial investigated the impact of testosterone replacement therapy (TRT) on prostate safety in men with hypogonadism. A total of 5,204 men aged 45-80 years were treated with topical 1.62% testosterone gel for an average of 21.8 months. The study found no significant difference in the incidence of
